A new study in Cell shows the structure of a kappa-opioid receptor in its active state with a biased agonist bound to it. Researchers say this could help them develop new non-addictive painkillers that only bind to kappa-opioid receptors.
Quell, from NeuroMetrix. Transcutaneous electrical nerve stimulator device fits in band worn around upper calf. "Stimulates sensory nerves, which leads to the release of endogeno (Wearable Technology Gadgets)
EMBEDA(TM) contains extended-release morphine pellets, each with an inner core of naltrexone hydrochloride, an opioid receptor antagonist. If taken as directed, the morphine relieves pain while the sequestered naltrexone hydrochloride passes through the body with no intended clinical effect. If EMBEDA(TM) is crushed or chewed, the naltrexone is released and absorbed with the morphine, reversing the morphine’s subjective and analgesic effects.
Low-dose naltrexone or LDN, a prescription drug classified as an opioid antagonist, may be one of the rare drugs that actually helps your body heal itself. It blocks opioid receptors and helps activate your body's immune system.
Opioids applied in a topical cream that directly target the peripheral opioid receptors (which grow in inflammatory pain sites to attract natural endorphin compounds for pain relief and immune enhancement) may have advantages relative to oral opioids.
How kappa opioid receptors drive anxiety
A cellular mechanism has been discovered by which kappa opioid receptors (KORs) drive anxiety. These proteins inhibit the release of the neurotransmitter glutamate in a part of the brain that regulates emotion. KORs are targets for the treatment of addiction and anxiety disorders.
Non-specific opioid receptor antagonists (e.g., naloxone [Narcan, antidote for heroin overdose]) as well as the mixed opioid agonist/antagonist buprenorphine [Subutex, used to facilitate narcotics withdrawal] can be used to reverse the effects of kappa agonists.
Scientists Just Solved a Major Piece of the Opioid Puzzle